Glenn J Jaffe1, Dean Eliott2, John A Wells3, Jonathan L Prenner4, Andras Papp5, Samir Patel6. 1. Department of Ophthalmology, Duke University, Durham, North Carolina. Electronic address: jaffe001@mc.duke.edu. 2. Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts. 3. Palmetto Retina Center, Columbia, South Carolina. 4. New Jersey Retina, Rutgers Medical School, Newark, New Jersey. 5. Semmelweis University, Budapest, Hungary. 6. Ophthotech, New York, New York.
Abstract
PURPOSE: To assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD). DESIGN: Prospective phase 1 clinical trial. PARTICIPANTS: A total of 23 participants diagnosed with NVAMD and aged 50 years or older were enrolled. METHODS:Part 1 included 15 participants. Three participants received a single intravitreal E10030 (0.03 mg) injection and were subsequently given intravitreal ranibizumab (0.5 mg) injections at weeks 2, 6, and 10. Twelve participants (3 per group) received E10030 (0.03, 0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) at day 0, month 1, and month 2 in an ascending manner. In Part 2 (8 participants), E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) was injected at day 0, month 1, and month 2. MAIN OUTCOME MEASURES: Safety at week 12 was the primary outcome and included assessment of vital signs, laboratory tests, and serial eye examinations. Other safety metrics included assessment through week 24 of Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and biomarker changes evaluated by optical coherence tomography (OCT) and fluorescein angiography (FA). RESULTS: All doses of intravitreal E10030 administered in combination with ranibizumab were well tolerated. No dose-limiting toxicities or relevant safety events were noted at any dose level during the study. Investigators did not report adverse events related to E10030 or ranibizumab. Mean VA change was a gain of 14 letters, and 59% of participants gained ≥15 letters from baseline at week 12. On FA at week 12, there was an 85.5% mean reduction from baseline in choroidal neovascularization (CNV) size. On OCT at the week 12 visit, there was a mean decrease in center point thickness and central subfield thickness of 38.9% and 33.7%, respectively. CONCLUSIONS: Intravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab.
RCT Entities:
PURPOSE: To assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD). DESIGN: Prospective phase 1 clinical trial. PARTICIPANTS: A total of 23 participants diagnosed with NVAMD and aged 50 years or older were enrolled. METHODS: Part 1 included 15 participants. Three participants received a single intravitreal E10030 (0.03 mg) injection and were subsequently given intravitreal ranibizumab (0.5 mg) injections at weeks 2, 6, and 10. Twelve participants (3 per group) received E10030 (0.03, 0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) at day 0, month 1, and month 2 in an ascending manner. In Part 2 (8 participants), E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) was injected at day 0, month 1, and month 2. MAIN OUTCOME MEASURES: Safety at week 12 was the primary outcome and included assessment of vital signs, laboratory tests, and serial eye examinations. Other safety metrics included assessment through week 24 of Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and biomarker changes evaluated by optical coherence tomography (OCT) and fluorescein angiography (FA). RESULTS: All doses of intravitreal E10030 administered in combination with ranibizumab were well tolerated. No dose-limiting toxicities or relevant safety events were noted at any dose level during the study. Investigators did not report adverse events related to E10030 or ranibizumab. Mean VA change was a gain of 14 letters, and 59% of participants gained ≥15 letters from baseline at week 12. On FA at week 12, there was an 85.5% mean reduction from baseline in choroidal neovascularization (CNV) size. On OCT at the week 12 visit, there was a mean decrease in center point thickness and central subfield thickness of 38.9% and 33.7%, respectively. CONCLUSIONS: Intravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab.
Authors: Raquel Lima E Silva; Yogita Kanan; Adam C Mirando; Jayoung Kim; Ron B Shmueli; Valeria E Lorenc; Seth D Fortmann; Jason Sciamanna; Niranjan B Pandey; Jordan J Green; Aleksander S Popel; Peter A Campochiaro Journal: Sci Transl Med Date: 2017-01-18 Impact factor: 17.956
Authors: Kun Ding; Lucia Eaton; Diana Bowley; Matthew Rieser; Qing Chang; Maria C Harris; Anca Clabbers; Feng Dong; Jikui Shen; Sean F Hackett; Debra S Touw; Jacqueline Bixby; Suju Zhong; Lorenzo Benatuil; Sahana Bose; Christine Grinnell; Gregory M Preston; Ramesh Iyer; Ramkrishna Sadhukhan; Susan Marchie; Gary Overmeyer; Tariq Ghayur; Deborah A van Riet; Shibo Tang; Peter A Campochario; Jijie Gu Journal: MAbs Date: 2017 Feb/Mar Impact factor: 5.857
Authors: Mingbing Zeng; Jikui Shen; Yuanyuan Liu; Lucy Yang Lu; Kun Ding; Seth D Fortmann; Mahmood Khan; Jiangxia Wang; Sean F Hackett; Gregg L Semenza; Peter A Campochiaro Journal: J Mol Med (Berl) Date: 2016-12-21 Impact factor: 4.599
Authors: Timothy L Jackson; David Boyer; David M Brown; Nauman Chaudhry; Michael Elman; Chris Liang; Denis O'Shaughnessy; Edward C Parsons; Sunil Patel; Jason S Slakter; Philip J Rosenfeld Journal: JAMA Ophthalmol Date: 2017-07-01 Impact factor: 7.389
Authors: Thiago Cabral; Luiz H Lima; Luiz Guilherme M Mello; Júlia Polido; Éverton P Correa; Akiyoshi Oshima; Jimmy Duong; Pedro Serracarbassa; Caio V Regatieri; Vinit B Mahajan; Rubens Belfort Journal: Ophthalmol Retina Date: 2018-01